FireEye, Inc. (NASDAQ:FEYE) notched a -2.18% intraday decline moving at $17.51. When the opening bell rang, the price was $17.92. The number of shares that were traded during the day was 3.63 million, which corresponds to its 3-month volume average of 5.1 million shares a day.FireEye, Inc. (FEYE) Analyst Opinion
FireEye, Inc. has a consensus outperform rating from 29 Wall Street analysts, and the number of shares currently sold short amount to at least 17.78% of shares outstanding. The stock spiked 6.7% last month and is up 47.14 this year. Wall Street is only getting more bullish on the stock, with 10 of analysts who cover FEYE having a buy-equivalent rating. Analysts have placed a $17.2 price target on FireEye, Inc., suggesting a -1.77% decline from recent close. It’s currently trading about -2.72% below its 52-week high.FireEye, Inc. Earnings Surprise
FireEye, Inc. (FEYE) surprised the stock market in its last reported earnings when it earned -$0.04 a piece versus the consensus-estimated -$0.12. Its revenue totaled $176.43 million up 1.55% from the previous quarter.
This stock (FEYE) is ahead of its 52-week low with 69.18%. Its last month’s stock price volatility remained 2.05% which for the week stands at 2.25%. The share price has moved forward from its 20 days moving average, trading at a distance of 2.16% and stays 12.38% away from its 50 days moving average. Over the last five days, shares have faced -0.06% losses and now is up 25.95% since hitting its 200-day moving average of $14.85. FireEye, Inc. (FEYE) has made its way to a 12-month gain of 27.25%.
Turning to Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK), its shares were trading at $13.13 a gain of $0.03, on the trading floor. The stock, after opening at $13.21, touched a high of $13.35 before paring much of its gains. So far, analysts are sticking with their bearish recommendations with the consensus call at 3. Merrimack Pharmaceuticals, Inc. has 0 buy ratings, 3 holds and 0 sells even after the stock tumbled -71.57% from its high of $67.9 to a $178.31 million market value through last close.Merrimack Pharmaceuticals, Inc. (MACK) Consensus Price Target
The company’s consensus rating on Reuter’s scale remained unchanged from 3 to 3 during a month. Analysts set a 12-month price target of $15 a share. The target implies a 14.24% spike from where the shares are currently trading. Also, the current price highlights a discount of 14.24% to analysts’ high consensus price target.Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) Intraday Trading
The counter witnessed a trading volume of 0.26 million shares versus an average volume of 0.19 million shares during last trading session. Its last month’s stock price volatility remained 5.46% which for the week approaches 4.9%. The lowest price the stock reached in the last trading day was $12.7 and compares with the $11.3 52-week low. The stock recovered 16.19% since its low point and has performed -52.69% year-to-date.